How Oncologists Perceive the Availability and Quality of Information Generated From Patient-Reported Outcomes (PROs)

被引:2
|
作者
Shea, Michael [1 ]
Audibert, Celine [2 ]
Stewart, Mark [1 ]
Gentile, Brittany [3 ]
Merino, Diana [1 ]
Hong, Agnes [4 ]
Lassiter, Laura [1 ]
Caze, Alexis [5 ]
Leff, Jonathan [6 ]
Allen, Jeff [1 ]
Sigal, Ellen [1 ]
机构
[1] Friends Canc Res, Washington, DC USA
[2] Deerfield Inst, Epalinges, Switzerland
[3] Genentech Inc, Patient Ctr Outcomes Res PCOR Grp, San Francisco, CA USA
[4] Genentech Inc, San Francisco, CA USA
[5] Deerfield Management, Res & Consulting Grp, New York, NY USA
[6] Deerfield Management, New York, NY USA
来源
JOURNAL OF PATIENT EXPERIENCE | 2020年 / 7卷 / 02期
关键词
cancer; health information technology; medical decision-making; survey data; CLINICAL-TRIALS; CARE;
D O I
10.1177/2374373519837256
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Despite increased incorporation of patient-reported outcome (PRO) measures into clinical trials, information generated from PROs remains largely absent from drug labeling and electronic health records, giving rise to concerns that such information is not adequately informing clinical practice. Objective: To evaluate oncologists' perceptions concerning the availability and quality of information generated from PRO measures. Additionally, to identify whether an association exists between perceptions of availability and attitudes concerning quality. Method: An online, 11-item questionnaire was developed to capture clinician perspectives on the availability and use of PRO data to inform practice. The survey also asked respondents to rate information on the basis of 4 quality metrics: "usefulness," "interpretability," "accessibility," and "scientific rigor." Results: Responses were received from 298 of 1301 invitations sent (22.9% response rate). Perceptions regarding the availability of PRO information differed widely among respondents and did not appear to be linked to practice setting. Ratings of PRO quality were generally consistent, with average ratings for the 4 quality metrics between "satisfactory" and "good." A relationship was observed between ratings of PRO data quality and perceptions of the availability. Conclusion: Oncologists' attitudes toward the quality of information generated from PRO measures are favorable but not enthusiastic. These attitudes may improve as the availability of PRO data increases, given the association we observed between oncologists' ratings of the quality of PRO information and their perceptions of its availability.
引用
收藏
页码:217 / 224
页数:8
相关论文
共 50 条
  • [1] Patient-Reported Outcomes (Pros) and Patient-Reported Outcome Measures (Proms)
    Weldring, Theresa
    Smith, Sheree M. S.
    HEALTH SERVICES INSIGHTS, 2013, 6 : 61 - 68
  • [2] Patient-reported outcomes (PROs) in chronic urticaria
    Moestrup, Kristian
    Ghazanfar, Misbah N.
    Thomsen, Simon F.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017, 56 (12) : 1342 - 1348
  • [3] PATIENT-REPORTED OUTCOMES (PROS) IN BLADDER CANCER
    Barsdorf, A., I
    Pease, S.
    VALUE IN HEALTH, 2015, 18 (03) : A210 - A210
  • [4] Patient-reported outcomes (PROs) versus patient-reported outcome measures (PROMs)Is there a difference?
    Jokstad, Asbjorn
    CLINICAL AND EXPERIMENTAL DENTAL RESEARCH, 2018, 4 (03): : 61 - 62
  • [5] Evaluating Treatment from the Point of View of the Patient - PROs (Patient-Reported Outcomes)
    Boerdlein-Wahl, Inge
    Hilpert, Felix
    Kohlmann, Thomas
    ONKOLOGIE, 2009, 32 : 18 - 20
  • [6] Patient-reported outcomes (PROS) in insomnia: An endpoint model
    Kleinman, L.
    Roth, T.
    Buysse, D.
    Kalsekar, A.
    Harding, G.
    Lichstein, K.
    Revicki, D.
    SLEEP, 2007, 30 : A231 - A231
  • [7] Using patient-reported outcomes (PROs) for symptom monitoring
    Lai-Kwon, Julia
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 106 - 106
  • [8] PATIENT-REPORTED OUTCOMES (PROS) IN DIABETES CLINICAL TRIALS
    Barsdorf, A., I
    Rubinstein, E.
    Jaksa, A.
    VALUE IN HEALTH, 2013, 16 (03) : A168 - A169
  • [9] Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)
    Anne Oberguggenberger
    Michael Hubalek
    Monika Sztankay
    Verena Meraner
    Beate Beer
    Herbert Oberacher
    Johannes Giesinger
    Georg Kemmler
    Daniel Egle
    Eva-Maria Gamper
    Barbara Sperner-Unterweger
    Bernhard Holzner
    Breast Cancer Research and Treatment, 2011, 128 : 553 - 561
  • [10] Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)
    Oberguggenberger, Anne
    Hubalek, Michael
    Sztankay, Monika
    Meraner, Verena
    Beer, Beate
    Oberacher, Herbert
    Giesinger, Johannes
    Kemmler, Georg
    Egle, Daniel
    Gamper, Eva-Maria
    Sperner-Unterweger, Barbara
    Holzner, Bernhard
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (02) : 553 - 561